Judy Ellen Garber MD

Oncology•Boston, MA

Breast Cancer, Cancer Genetics/Cancer Risk Assessment, Hematologic Oncology

Professor of Medicine, Dana-Farber Cancer Institute

Join to View Full Profile

44 Binney StSM 209Boston, MA 02115
Phone+1 617-632-5770
Fax+1 617-632-2649

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1985 - 1989
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1984 - 1985
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1981 - 1984
Yale School of MedicineClass of 1981

Certifications & Licensure

MA State Medical License 1984 - 2027
CT State Medical License 2022 - 2026
NH State Medical License 2023 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
Boston Magazine Castle Connolly, 2008-2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Fellow (FASCO) American Society of Clinical Oncologists, 2008
Boston Herald Castle Connolly, 2005
Redbook Magazine: Top Breast Cancer Doctors Castle Connolly, 2001
Elected Member The American Society for Clinical Investigation, 2001
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Prevention of Depression in At-Risk Adolescents Start of enrollment: 2003 Mar 01
Completed
Not Applicable
Letrozole in Preventing Breast Cancer in Postmenopausal Women Start of enrollment: 2002 Feb 01
Completed
Phase 2
Preoperative Cisplatin in Early Stage Breast Cancer Start of enrollment: 2004 Jul 01
Completed
Phase 2
Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing Start of enrollment: 1998 Jul 01
Completed
Not Applicable
Effects of Tibilone on Bone Density, Menopause Symptoms and Breast Density in Women After Prophylactic Oophorectomy Start of enrollment: 2004 Apr 01
Completed
Phase 2
Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors Start of enrollment: 2001 Apr 01
Completed
Not Applicable
Telephone-Based Genetic Counseling or Standard Genetic Counseling in Women at Risk of Carrying the BRCA1 or BRCA2 Mutation Start of enrollment: 2005 May 01
Completed
Not Applicable
Cognitive Behavioral vs. Interpersonal Therapy (IPT) Prevention of Depression in Adolescents Start of enrollment: 2004 Jan 01
Completed
Not Applicable
Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer Start of enrollment: 2006 Jul 01
Completed
Phase 2
Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ Start of enrollment: 2009 Aug 19
Completed
Not Applicable
Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients Start of enrollment: 2008 Nov 12
Completed
Phase 1
Statins and Breast Cancer Biomarkers Start of enrollment: 2005 Jan 01
Unknown status
Phase 2
Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer Start of enrollment: 2010 Jun 30
COMPLETED
PHASE2
Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors
ACTIVE_NOT_RECRUITING
PHASE2
Vitamin D and Breast Cancer Biomarkers in Female Patients
COMPLETED
PHASE3
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer Start of enrollment: 2011 Jan 01
Terminated
Phase 2
Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa
COMPLETED
PHASE2
Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors Start of enrollment: 2013 May 01
Completed
Phase 2
A Family Depression Prevention Program Start of enrollment: 2014 Aug 01
Completed
Not Applicable
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer Start of enrollment: 2014 Apr 22
ACTIVE_NOT_RECRUITING
PHASE3
Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer Start of enrollment: 2016 Jun 14
Completed
Phase 2
Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast Start of enrollment: 2018 Jan 30
Completed
Phase 2
Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress Start of enrollment: 2020 Sep 15
Recruiting
Olaparib in Metastatic Breast Cancer Start of enrollment: 2018 Apr 01
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Contact
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation Start of enrollment: 2023 Feb 14
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Principal Investigator, Contact, Study Chair
Join now to see all

Publications & Presentations

PubMed

Corrigendum to "HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome" [Eur J Cancer 211 (2024) 114307].
Michele Bottosso, Renata L Sandoval, Benjamin Verret, Natalia Polidorio, Olivier Caron
European Journal of Cancer. 2025-05-02
Low allele frequency variants identified on germline multi-gene panel testing for cancer predisposition can suggest the presence of constitutional mosaicism.
Adela Rodriguez-Hernandez, Linda M Polfus, Brittany L Bychkovsky, Beth Souders, Aleix Prat
Clinical Cancer Research. 2025-04-21
Video Education Is an Acceptable Alternative to Pretest Genetic Counseling for Patients With Breast, Ovarian, Pancreatic, and Metastatic Prostate Cancer: Results From ...
Katherine A Schneider, Lauren Massingham, Michelle Weitz, Chanika Phornphutkul, Melissa Leach
JCO Oncology Practice. 2025-04-10

Journal Articles

Screening with Whole-Body Magnetic Resonance Imaging in Pediatric Subjects with Li–Fraumeni Syndrome: A Single Institution Pilot Study
Judy E Garber, Lisa Diller, Junne Kamihara, Allison F O'Neill, Pediatric Blood & Cancer

Abstracts/Posters

Low-Dose Tamoxifen (LDTam) As a Breast Cancer (BC) Risk-Reduction Strategy in Lymphoma Survivors Exposed to Chest Radiation Therapy (RT) during Adolescence/Young Adult...
Judy Garber, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Advances in Germline Genetics: What Surgeons Need to Know
Boston, MA - 10/28/2014

Press Mentions

How Can I Reduce My Risk of Cancer?April 15th, 2025
OlympiA Trial: Long-Term Benefits of Olaparib Confirmed in High-Risk Subgroup of Breast CancerJanuary 25th, 2025
Olaparib Shows Long-Term Benefit in High-Risk BRCA1/2-Mutated Breast CancerJanuary 7th, 2025
Join now to see all

Grant Support

Precision approaches to refining TP53-associated cancer riskBECKMAN RESEARCH INSTITUTE/CITY OF HOPE2019–2025
Discovery, Biology And Risk Of Inherited Variants In Breast CancerNational Cancer Institute2010–2011
Epidemiology Of Syndromic GI Stromal TumorsNational Cancer Institute2007–2010
Pilot Study Of Aromatase InhibitorsNational Center For Research Resources2004–2008
Process &Outcomes Of Brcal/2 Clinical TestingNational Human Genome Research Institute2002–2003
Breast Cancer Prevention In Hodgkins DiseaseNational Cancer Institute2001–2002
Plasma Estrogens In Breast Cancer Risk And PreventionNational Cancer Institute2000–2002
Process &Outcomes Of BRCA1/2 Clinical TestingNational Human Genome Research Institute2001
Randomized Study--Brca1/2 Genetic V Consent CounselingNational Human Genome Research Institute1997–2001
Treatment Of Depression In Parents--Impact On ChildrenNational Institute Of Mental Health1998
Predictive Testing Program For P53 Mutations In LfsNational Human Genome Research Institute1994–1996
Dissemination Of A Brcal Predisposition Testing ProgramNational Human Genome Research Institute1994–1996
Development Of Depression In Children And AdolescentsNational Institute Of Mental Health1991–1995